In April 2025, Wuhan Jinglong Biotechnology Co., Ltd. officially entered into a strategic cooperation agreement with the Peking Union Medical College Institute of Materia Medica. As part of this collaboration, the Institute has authorized our company to establish the National Engineering Research Center for New Drug Development—Pilot Research Base for Pet Orally Dissolving Film Technology. This initiative aims to integrate the complementary strengths of both parties, focusing on the R&D and industrial application of orally dissolving films (ODFs) as an innovative drug delivery technology. This milestone represents a solid step forward in the company’s strategic layout in the ODF formulation field.

Wuhan Jinglong Biotechnology’s R&D team has dedicated over ten years to the development of ODF technology, accumulating deep expertise in film formulation processes, raw material research, and process control. The company boasts a comprehensive product chain and leads core technological development and product operation at the research center. The Peking Union Medical College Institute of Materia Medica will contribute its profound knowledge in traditional Chinese medicine, natural products, and food-medicine homology, supported by robust technical capabilities. The Institute will provide scientific and high-quality guidance to enhance the professional development of products throughout R&D and application phases. By combining their respective advantages, the two parties aim to build a complete value chain from research to market.

Orally dissolving film formulations represent an advanced drug delivery technology that dissolves rapidly in the oral cavity without the need for water. They offer notable benefits such as convenience of administration, rapid onset of action, and effective taste masking, significantly improving patient compliance. These characteristics make ODFs particularly suitable for children, the elderly, individuals with swallowing difficulties, and pets. As such, ODFs have garnered widespread attention in global markets and hold promising application prospects.
This collaboration stems from a shared insight into industry innovation trends and mutual recognition of each other’s technical capabilities and resources. ODF technology represents a major direction in modern pharmaceutical formulation development, and this partnership exemplifies the efficient integration of technological R&D and industrial resources. Both parties expressed: “We look forward to the Pilot Research Base for Pet Orally Dissolving Film Technology accelerating the translation of innovative achievements into market-ready products, providing more high-quality and effective nutrient-based product options, and empowering the long-term development of the company.”
The key focus areas of the Pilot Research Base for Pet Orally Dissolving Film Technology will include:
• Core Technology Breakthroughs: Tackling common technical challenges in raw materials, processes, equipment scaling, and stability of ODF formulations.
• Industrialization and Quality Research: Establishing internationally aligned quality control standards and scalable production processes to ensure product safety, efficacy, and quality consistency.

The establishment of the Pilot Research Base marks a significant milestone in the development of Wuhan Jinglong Biotechnology. It not only demonstrates the company’s innovative capabilities but also represents a critical step in proactively responding to market changes and planning for the future. This in-depth collaboration is expected to inject new momentum into both parties’ growth, promote the overall advancement and industrial upgrading of ODF technology in China, and provide a wider range of options and diverse application scenarios. It will also introduce more possibilities for warm and meaningful human-pet interactions, contributing to a new chapter of depth and warmth in the relationship between humans and their pets.
About Us+
Product Center+
Service +
News+
Scan WeChat